Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma Inc (NQ: LYEL )

1.120 +0.160 (+16.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lyell Immunopharma Inc

< Previous 1 2 3 4 Next >
Lyell Immunopharma to Participate in Barclays Virtual Fireside Chat Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
GSK Walks Away From T-Cell Therapy Pact With Lyell Citing Strategic Actions
Via Benzinga
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Analyst Sees A Leader In Solid Tumor Cell Therapy In This Stock
Via Benzinga
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022
Upgrades 
Via Benzinga
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Lyell Immunopharma, Inc
Via GlobeNewswire
Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
5 Value Stocks In The Healthcare Sector
What are Value Stocks? 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Why U.S. Stocks Are Trading Lower; AZZ Earnings And More
U.S. stocks traded lower this morning as investors digested the recent jobs report for the month of June. 
Via Benzinga
Biotech ETF Tops in June: 5 Stocks That Outperform
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%. 
Via Talk Markets
89 Biggest Movers From Friday
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
FDA Clears Lyell Immunopharma' LYL132 Trial For Solid Tumors
The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors.... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a... 
Via Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
54 Biggest Movers From Friday
Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc.... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 35.02% to $7.22 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Progenity (NASDAQ:PROG) shares increased by 17.0% to $1.1 during Tuesday's regular session. As of 12:30 EST, this security is trading at a volume of 40.5... 
Via Benzinga
72 Biggest Movers From Yesterday
Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.